MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Amneal Pharmaceuticals Retained Earnings 2011-2026 | AMRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Amneal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -535 M | -607 M | -490 M | -406 M | -276 M | -287 M | -378 M | -20.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.9 M | -607 M | -375 M |
Quarterly Retained Earnings Amneal Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -570 M | -572 M | -595 M | -576 M | -576 M | -582 M | - | -401 M | -413 M | -406 M | -402 M | -399 M | -278 M | -276 M | -270 M | -266 M | -280 M | -287 M | -287 M | -287 M | -287 M | -378 M | -378 M | -378 M | -378 M | -20.9 M | -20.9 M | -20.9 M | -20.9 M | -383 M | -383 M | -383 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -20.9 M | -595 M | -347 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-972 M | $ 2.13 | -12.55 % | $ 219 M |  USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
-152 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-487 M | $ 2.4 | -2.83 % | $ 132 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-650 M | $ 1.64 | -1.8 % | $ 4.16 M | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
-407 M | $ 1.44 | 6.3 % | $ 58.1 M | USA |
 |
Cabaletta Bio
CABA
|
-233 M | $ 3.34 | 0.6 % | $ 3.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.7 | 2.49 % | $ 1.11 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
-563 M | $ 1.05 | 3.47 % | $ 77.1 M | USA |
 |
Cerus Corporation
CERS
|
-1.07 B | $ 2.6 | 1.56 % | $ 480 M | USA |
 |
Certara
CERT
|
-130 M | $ 7.17 | 1.27 % | $ 1.15 B | USA |
 |
Cullinan Management
CGEM
|
-368 M | $ 15.91 | 2.65 % | $ 931 M | USA |
 |
Compugen Ltd.
CGEN
|
-489 M | $ 2.28 | 25.97 % | $ 204 M | Israel |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
-1.58 B | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 3.88 | - | $ 116 M | France |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-84.4 M | $ 3.1 | -0.44 % | $ 1.18 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Cocrystal Pharma
COCP
|
-333 M | $ 1.02 | -0.97 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Collegium Pharmaceutical
COLL
|
-101 M | $ 42.0 | 0.79 % | $ 1.33 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
643 M | $ 35.61 | -0.25 % | $ 3.7 B | USA |
 |
Athira Pharma
ATHA
|
-406 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |